Eagle Pharmaceuticals Inc (NAS:EGRX)
$ 3.92 0.18 (4.81%) Market Cap: 50.80 Mil Enterprise Value: 104.72 Mil PE Ratio: 4.31 PB Ratio: 0.20 GF Score: 60/100

Eagle Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 14, 2020 / 07:00PM GMT
Release Date Price: $37.96 (+2.54%)
Arek Kurkciyan;Morgan Stanley;Managing Director;Scott L. Tarriff<

Hi, everybody. You have Arek Kurkciyan here from Morgan Stanley's Healthcare Investment Banking team. I want to kick off with a quick webcast disclaimer for the group here, and then I'll introduce the participants we have from Eagle Pharmaceuticals. Please note that this webcast is for Morgan Stanley's clients and appropriate Morgan Stanley employees only. This webcast is not for members of the press. If you are a member of the press, please disconnect and reach out separately. For important disclosures please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.

So thank you for that. With that, let me introduce Scott Tarriff, Founder and CEO of Eagle Pharmaceuticals; and Pete Meyers, CFO of Eagle Pharmaceuticals. Thanks for having -- or joining us here, Scott and Pete.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot